Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.

Ewelina Mamcarz,Sheng Zhou,Timothy D. Lockey,Hossam Abdelsamed,Shane J. Cross,Guolian Kang,Zhijun Ma,Jose Condori,Jola Dowdy,Brandon Triplett,Chen Li,Gabriela Maron,Juan C. Aldave-Becerra,Joseph A. Church,Elif Dokmeci,James T. Love,Ana C. da Matta Ain,Hedi van der Watt,Xing-tang,William J. Janssen,Byoung Y. Ryu,Suk-See de Ravin,Mitchell J. Weiss,Benjamin Youngblood,Janel Long-Boyle,Stephen Gottschalk,Michael M. Meagher,Harry L. Malech,Jennifer M. Puck,Morton J. Cowan,Brian P. Sorrentino

Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.

2019

Abstract Background Allogeneic hematopoietic stem-cell transplantation for X-linked severe combined immunodeficiency (SCID-X1) often fails to reconstitute immunity associated with T cells, B cells,...

Keywords:

Diabetes mellitus
Surgery
Oncology
Busulfan
Medicine
Genetic enhancement
Internal medicine
Transplantation Conditioning
Immunity
Hematopoietic stem cell transplantation
Severe combined immunodeficiency
Transplantation
Immunology
X-Linked Combined Immunodeficiency Diseases

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

105

Citations